Tapinarof to treat psoriasis

K. Rodríguez Baisi, Megha Tollefson

Research output: Contribution to journalArticlepeer-review


There is a need for new and effective topical treatment options for psoriasis. Recent phase I and II clinical trials have demonstrated efficacy of the novel nonsteroidal drug tapinarof to treat mild to moderate plaque psoriasis. Tapinarof is an aryl hydrocarbon receptor (AHR) agonist that induces antioxidant, immunomodulatory and epidermal differentiation regulation pathways. In this review, we examine the current preclinical and clinical studies with a focus on the mechanism of action, pharmacokinetics, safety and efficacy of tapinarof to treat psoriasis.

Original languageEnglish (US)
Pages (from-to)515-530
Number of pages16
JournalDrugs of Today
Issue number8
StatePublished - Aug 2020


  • Antipsoriatics
  • Aryl hydrocarbon receptor (AHR) agonists
  • Dermatological disorders
  • Psoriasis
  • Tapinarof

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Tapinarof to treat psoriasis'. Together they form a unique fingerprint.

Cite this